Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma
- PMID: 23287851
- DOI: 10.1097/JTO.0b013e318279d503
Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma
Abstract
Introduction: We have recently shown that the protein C4.4A is induced in early precursor lesions of pulmonary adenocarcinomas and squamous cell carcinomas. In the present study, we aimed at analyzing the impact of C4.4A on the survival of non-small cell lung cancer patients and determining whether its unexpected expression in adenocarcinomas could be attributed to a specific growth type (lepidic, acinar, papillary, micropapillary, solid).
Methods: Sections from the center and periphery of the primary tumor, as well as N2-positive lymph node metastases, were stained by immunohistochemistry for C4.4A and scored semi-quantitatively for intensity and frequency of positive tumor cells.
Results: C4.4A score (intensity × frequency) in the tumor center was a highly significant prognostic factor in adenocarcinomas (n = 88), both in univariate (p = 0.004; hazard ratio [95% confidence interval] = 1.44 [1.12-1.85]) and multivariate statistical analysis (p = 0.0005; hazard ratio = 1.65 [1.24-2.19]), demonstrating decreasing survival with increasing score. In contrast, C4.4A did not provide prognostic information in squamous cell carcinomas (n = 104). Pathological stage was significant in both groups. In the adenocarcinomas, C4.4A expression was clearly associated with, but a stronger prognostic factor than, solid growth.
Conclusions: The present results substantiate the potential value of C4.4A as a prognostic marker in pulmonary adenocarcinomas seen earlier in a smaller, independent patient cohort. Importantly, we also show that C4.4A is a surrogate marker for adenocarcinoma solid growth. Recent data suggest that C4.4A is negatively regulated by the tumor suppressor liver kinase B1, which is inactivated in some adenocarcinomas, providing a possible link to the impact of C4.4A on the survival of these patients.
Similar articles
-
Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237. J Thorac Oncol. 2013. PMID: 23287853
-
Prognostic significance of TAZ expression in resected non-small cell lung cancer.J Thorac Oncol. 2012 May;7(5):799-807. doi: 10.1097/JTO.0b013e318248240b. J Thorac Oncol. 2012. PMID: 22481233
-
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015. PLoS One. 2015. PMID: 26313362 Free PMC article.
-
Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.Surg Oncol. 2015 Dec;24(4):329-34. doi: 10.1016/j.suronc.2015.09.001. Epub 2015 Sep 14. Surg Oncol. 2015. PMID: 26690822 Review.
-
The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition.Curr Med Chem. 2008;15(25):2559-73. doi: 10.2174/092986708785909012. Curr Med Chem. 2008. PMID: 18855679 Review.
Cited by
-
C4.4A gene ablation is compatible with normal epidermal development and causes modest overt phenotypes.Sci Rep. 2016 May 12;6:25833. doi: 10.1038/srep25833. Sci Rep. 2016. PMID: 27169360 Free PMC article.
-
C4.4A as a biomarker of head and neck squamous cell carcinoma and correlated with epithelial mesenchymal transition.Am J Cancer Res. 2015 Nov 15;5(12):3505-15. eCollection 2015. Am J Cancer Res. 2015. PMID: 26885441 Free PMC article. Review.
-
Evolution and Medical Significance of LU Domain-Containing Proteins.Int J Mol Sci. 2019 Jun 5;20(11):2760. doi: 10.3390/ijms20112760. Int J Mol Sci. 2019. PMID: 31195646 Free PMC article. Review.
-
Expression of C4.4A in an In Vitro Human Tissue-Engineered Skin Model.Biomed Res Int. 2017;2017:2403072. doi: 10.1155/2017/2403072. Epub 2017 Sep 7. Biomed Res Int. 2017. PMID: 29075641 Free PMC article.
-
Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma.Cancer Cell Int. 2021 Dec 6;21(1):652. doi: 10.1186/s12935-021-02358-0. Cancer Cell Int. 2021. PMID: 34872577 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous